VivoSeq
Other

Liposomal Bupivacaine

0

Pipeline Programs

21

Active Trials

1

Companies Involved

Liposomal Bupivacaine is an early-stage landscape with 0 programs across 1 company. The most active players are Pacira Pharmaceuticals, Inc.

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

22/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

100

clinical trials

Completed47 · 47%
Terminated15 · 15%
Recruiting14 · 14%
Unknown status10 · 10%
Withdrawn7 · 7%
Not yet recruiting3 · 3%
Other4 · 4%

Trial Activity

100 trials

Liposomal Bupivacaine vs Ropivacaine for TAPBs
Recruiting·SSun Yat-sen University·Phase 3·NCT06430112·74 enrolled
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Recruiting··Phase 3·NCT06284434·60 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)